Top

Published in:

01-04-2020 | Radionuclide Therapy | Research Article

Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403

Authors: Xiaoxi Ling, Joseph D. Latoche, Cindy J. Choy, Brenda F. Kurland, Charles M. Laymon, Yijen Wu, Nathan Salamacha, Ding Shen, Jonathan J. Geruntho, Lora H. Rigatti, Hillarie P. Windish, Beatrice Langton-Webster, Clifford E. Berkman, Carolyn J. Anderson

Published in: Molecular Imaging and Biology | Issue 2/2020

Abstract

Purpose

Prostate-specific membrane antigen (PSMA) continues to be the hallmark biomarker for prostate cancer as it is expressed on nearly all prostatic tumors. In addition, increased PSMA expression correlates with castration resistance and progression to the metastatic stage of the disease. Recently, we combined both an albumin-binding motif and an irreversible PSMA inhibitor to develop the novel PSMA-targeted radiotherapeutic agent, CTT1403. This molecule was novel in the field of PSMA-targeted agents as its key motifs resulted in extended blood circulation time and tumor uptake, rapid and extensive internalization into PSMA+ cells, and promising therapeutic efficacy. The objective of this study was to perform IND-enabling translational studies on CTT1403 in rodent models.

Procedures

A dose optimization study was performed in PC3-PIP (PSMA+) tumor-bearing mice. Treatment groups were randomly selected to receive one to three 14-MBq injections of CTT1403. Control groups included (1) saline, (2) non-radioactive [¹⁷⁵Lu]CTT1403, or (3) two injections of 14 MBq CTT1751, a Lu-177-labeled non-targeted albumin-binding moiety. Tumor growth was monitored up to 120 days. Small-animal single photon emission tomography/X-ray computed tomography imaging was performed with CTT1403 and CTT1751 in PC3-PIP tumor-bearing mice to visualize infiltration of the Lu-177-labeled agent into the tumor. In preparation for a first-in-human study, human absorbed doses were estimated based on rat biodistribution out to 5 weeks to determine a safe CTT1403 therapy dose in humans.

Results

Two to 3 injections of 14 MBq CTT1403 yielded significant tumor growth inhibition and increased survival compared with all control groups and mice receiving 1 injection of 14 MBq CTT1403. Five of 12 mice receiving 2 or 3 injections of CTT1403 survived to the 120-day post-treatment study endpoint. Dosimetry identified the kidneys as the dose-limiting organ, with an equivalent dose of 5.18 mSv/MBq, resulting in a planned maximum dose of 4.4 GBq for phase 1 clinical trials.

Conclusions

The preclinical efficacy and dosimetry of CTT1403 suggest that this agent has significant potential to be safe and effective in humans.

Available only for authorised users

von Eyben FE, Baumann GS, Baum RP (2018) PSMA diagnostics and treatments of prostate cancer become mature. Clin Trans Imag 6:145–148CrossRef

Zschaeck S, Lohaus F, Beck M, Habl G, Kroeze S, Zamboglou C, Koerber SA, Debus J, Hölscher T, Wust P, Ganswindt U, Baur ADJ, Zöphel K, Cihoric N, Guckenberger M, Combs SE, Grosu AL, Ghadjar P, Belka C (2018) PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiat Oncol 13:90CrossRef

Huang SS, Heston WDW (2017) Should low molecular weight PSMA targeted ligands get bigger and use albumin ligands for PSMA targeting? Theranostics 7:1940–1941CrossRef

Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell E, Purnell G, Tyson I, Heal A, Abdel-Nabi H, Winzelberg G (1991) Immunoscintigraphy of prostatic cancer: preliminary results with ¹¹¹In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 18:229–241CrossRef

Pandit-Taskar N, O’Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gonen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ (2015) A phase I/II study for analytic validation of ⁸⁹Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res 21:5277–5285CrossRef

Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, Mier W, Iagaru AH, Herfarth K, Haberkorn U, Debus J, Giesel FL (2017) ⁶⁸Ga-PSMA-11 PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med 58:1943–1948CrossRef

Gallivanone F, Valente M, Savi A et al (2017) Targeted radionuclide therapy: frontiers in theranostics. Front Biosci 22:1750–1759CrossRef

Dash A, Pillai MR, Knapp FF Jr (2015) Production of ¹⁷⁷Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imag 49:85–107CrossRef

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ (2017) German multicenter study investigating ¹⁷⁷Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85–90CrossRef

10.

Pillai MRA, Nanabala R, Joy A, Sasikumar A, (Russ) Knapp FF (2016) Radiolabeled enzyme inhibitors and binding agents targeting PSMA: effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol 43:692–720CrossRef

11.

Choy CJ, Ling X, Geruntho JJ, Beyer SK, Latoche JD, Langton-Webster B, Anderson CJ, Berkman CE (2017) ¹⁷⁷Lu-labeled phosphoramidate-based PSMA inhibitors: the effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice. Theranostics 7:1928–1939CrossRef

12.

Lenth R Esimated marginal means, aka least-square means. https://CRAN.R-project.org/package=emmeans. Accessed 7 Dec 2018

13.

Cory E, Nazarian A, Entezari V, Vartanians V, Müller R, Snyder BD (2010) Compressive axial mechanical properties of rat bone as functions of bone volume fraction, apparent density and micro-ct based mineral density. J Biomech 43:953–960CrossRef

14.

Kirschner AS, Ice RD, Beierwaltes WH (1975) Radiation-dosimetry of I-131-19-iodocholesterol - pitfalls of using tissue concentration data - reply. J Nucl Med 16:248–249

15.

Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027PubMed

16.

Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, Drzezga A, Wild M (2016) Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [¹⁷⁷Lu]DKFZ-PSMA-617. Mol Imag Biol 18:437–445CrossRef

17.

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C (2017) Post-therapeutic dosimetry of ¹⁷⁷Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Nucl Med Commun 38:91–98CrossRef

18.

Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U (2014) Radiation dosimetry and first therapy results with a ¹²⁴I/ ¹³¹I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 41:1280–1292CrossRef

19.

Kramer CY (1956) Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 12:307–310CrossRef

20.

Aggarwal S, Ricklis RM, Williams SA, Denmeade SR (2006) Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. Prostate 66:903–910CrossRef

21.

Benesova M, Umbricht CA, Schibli R, Muller C (2018) Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm 15:934–946CrossRef

22.

Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C, Schlyer D, Zhao Y, Kim D, Babich JW (2018) Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur J Nucl Med Mol Imaging 45:1841–1851CrossRef

23.

Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, Colpo N, Lin KS, Bénard F (2018) Enhancing treatment efficacy of ¹⁷⁷Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies. Mol Pharm 15:5183–5191CrossRef

24.

Umbricht CA, Benesova M, Schibli R, Muller C (2018) Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm 15:2297–2306CrossRef

25.

Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, Kiesewetter DO, Jacobson O, Chen X (2018) Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors. Bioconjug Chem 29:3213–3221CrossRef

26.

Shargel L, Wu-Pong S, Yu ABC (2012) Multiple-dosage regimens. In: Applied biopharmaceutics & pharmacokinetics, 6th edn. The McGraw-Hill Companies, New York, p 153–176

27.

Emami B, Lyman J, Brown A, Cola L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122CrossRef

28.

Loke KSH, Padhy AK et al (2011) Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review. World J Nucl Med 10:122–138CrossRef

29.

Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G (2016) Dosimetry for Lu-177-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 43:42–51CrossRef

30.

Ilan E, Sandstrom M, Wassberg C, Sundin A, Garske-Roman U, Eriksson B, Granberg D, Lubberink M (2015) Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using ¹⁷⁷Lu-DOTATATE. J Nucl Med 56:177–182CrossRef

31.

Garske-Roman U, Sandstrom M, Fross Baron K et al (2018) Prospective observational study of ¹⁷⁷Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging 45:970–988CrossRef

32.

Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, Baio SM, Sansovini M, Paganelli G (2008) Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35:1847–1856CrossRef

33.

Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ (2005) Pharmacokinetics and biodistribution of In-111-Lu-177-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of Y-90-J591 radiation dosimetry based on In-111 or Lu-177? J Nucl Med 46:634–641PubMed

34.

Kurth J, Krause BJ, Schwarzenbock SM, Stegger L, Schafers M, Rahbar K (2018) External radiation exposure, excretion, and effective half-life in ¹⁷⁷Lu-PSMA-targeted therapies. EJNMMI Res 8:32CrossRef

35.

Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, Li F, Jacobson O, Niu G, Zhu Z, Chen X (2019) First-in-human study of ¹⁷⁷Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 46:148–158CrossRef

Title: Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403
Authors: Xiaoxi Ling
Joseph D. Latoche
Cindy J. Choy
Brenda F. Kurland
Charles M. Laymon
Yijen Wu
Nathan Salamacha
Ding Shen
Jonathan J. Geruntho
Lora H. Rigatti
Hillarie P. Windish
Beatrice Langton-Webster
Clifford E. Berkman
Carolyn J. Anderson
Publication date: 01-04-2020
Publisher: Springer International Publishing
Keyword: Radionuclide Therapy
Published in: Molecular Imaging and Biology / Issue 2/2020
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-019-01404-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Imaging Sigma-1 Receptor (S1R) Expression Using Iodine-124-Labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([124I]IPAG)

Targeting VPAC1 Receptors for Imaging Glioblastoma

Distribution of Brown Adipose Tissue Radiodensity in Young Adults: Implications for Cold [18F]FDG-PET/CT Analyses

[89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model

Quantitative Rodent Brain Receptor Imaging

Correction to: Performance Evaluation of a Newly Developed MR-Compatible Mobile PET Scanner with Two Detector Layouts